| 摘要 |
Disclosed are N-(3-{ [alkoxyphenyl]amino} quinoxalin-2-yl)-sulfonamides as represented by the general formula (I), wherein R1 is hydrogen or alkyl; R2 is selected from (CH2)m-R4, (CH2)m-CH(R4)2, CH(R4)2, CH((CH2)mOH)2, CH((CH2)m-alkoxy)2, CO-R4' and SO2-R4'; R3 is alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (CH2)m-S-alkyl, (CH2)m-SO2-alkyl, (CH2)m-alkoxy; and wherein the remaining substituents are as defined herein. Further disclosed is a pharmaceutical composition which contains at least one quinoxaline compound as defined above and a pharmaceutically acceptable carrier, diluent or excipient thereof for the treatment of diseases / conditions such as chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, B cell malignancies, hematopoietic cancers such as lymphomas, Hodgkin- and non-Hodgkin lymphomas, T-cell lymphomas, B-cell lymphomas, mantle cell lymphoma, leukaemia, myelomas, plasmacytomas, Waldenstroem macroglobulinemia, myelodysplastic syndrome, myeloproliferative disorders, chronic myelomonocytic leukemias, angiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, graft rejection, glomerulosclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung and in general lung airways inflammation.
|
